Your browser doesn't support javascript.
loading
Is There a Role for Temozolomide in Glioma Related Seizures? A Systematic Review.
Yue, Jiong; Yin, Cheng; Chen, Longyi; Xu, Ruxiang; Zhao, Dongdong.
Afiliación
  • Yue J; Department of Neurosurgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
  • Yin C; Department of Neurosurgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
  • Chen L; Department of Neurosurgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
  • Xu R; Department of Neurosurgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
  • Zhao D; Department of Neurosurgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
Neurol India ; 70(3): 864-871, 2022.
Article en En | MEDLINE | ID: mdl-35864610
Background: Seizures often herald the clinical appearance of glioma. Temozolomide (TMZ) is the first-line chemotherapeutic agent that has been used to treat glioma. Objective: We conducted a systematic review to determine seizure outcomes in glioma patients treated with TMZ. Methods and Material: We searched EMBASE and PubMed databases (January 1, 2003-August 26, 2021) by using search terms closely related to glioma, seizure, and temozolomide. Titles, abstracts, and full texts were screened and selected using previously established inclusion and exclusion criteria. The research team members reviewed potential articles and reached a consensus on the final articles to be included. Results: Nine studies containing data from three continents met our inclusion criteria. From several descriptive studies on low-grade gliomas (LGGs), the percentage of patients with partial seizure control after TMZ treatment ranged from 29% to 89.7%, and the percentage of patients with complete seizure control after TMZ ranged from 19.4% to 72%. In a retrospective cohort study of patients with LGGs, there was a marked difference in decreased seizure frequency between patients receiving TMZ and those who did not receive TMZ. In a randomized trial, TMZ seemed to have little effect on seizure control in elderly patients with glioblastoma. Conclusions: At present, there are few high-quality and well-designed clinical studies on TMZ for gliomas-related seizures. In terms of the literature included in this review, TMZ has an inhibitory effect on epilepsy. More randomized controlled trials are needed to elucidate the clinical benefits of TMZ in the treatment of gliomas-related seizures.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioma Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies / Systematic_reviews Límite: Aged / Humans Idioma: En Revista: Neurol India Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: India
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioma Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies / Systematic_reviews Límite: Aged / Humans Idioma: En Revista: Neurol India Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: India